Hemant Kumar, Ph.D., CPM, EMBA

Chief Manufacturing & Technology Officer

Dr. Kumar is a recognized global expert in Chemistry, Manufacture and Controls (CMC) Technical Development and GMP manufacturing. Prior to joining Genprex in September 2021, Dr. Kumar was Vice President, Global Head of Manufacturing, Supply Chain, and Strategy for Arcturus Therapeutics, Inc. Prior to that, Dr. Kumar was Vice President of CMC Technical Development & Manufacturing Operations at Oncoimmune Therapeutics, Inc., a private company that was acquired by Merck & Co. during his tenure there.  Before that, he was Vice President, Head of Global Process Sciences and Clinical Manufacturing Operations at Rentscher BioPharma, SE. Previous to that, Dr. Kumar was with Anaptysbio, Inc., where he served as Senior Vice President, Head of Global CMC, Technical Development and Manufacturing Operations. Before that, Dr. Kumar held senior level positions of increasing manufacturing and technical operations leadership in global biopharmaceutical companies including Merck & Co., Inc., Sanofi Genzyme, Inc., Lonza Biologics, Inc., Sanofi Pasteur, Janssen Biotech (a Johnson & Johnson company) and Wyeth Lederle Vaccines, Inc.

Dr. Kumar earned his Ph.D. in Biochemistry at J.N. Medical College, Aligarth India through a collaboration with the U.S. National Institute of Health. He holds a graduate certificate in Project Management from Lehigh University.  Dr. Kumar has conducted postdoctoral and research scientist fellowships at Yale University School of Medicine’s Howard Hughes Research Center and at the University of Rhode Island and the Center for Disease Control and Prevention’s Center for Infectious Diseases.  He holds professional affilations with the American Chemical Society, American Association for the Advancement of Science, Americal Society for Microbiology and the International Society of Pharmaceutical Engineers.


  • 25+-year track record leading global CMC and regulatory approval strategy for accelerated development of innovative vaccines, biologics, advanced cell & gene therapy drug process and product development (Ph1 to Ph3 and commercialization) under current GMP, and licensing processes
  • Six Sigma Champion and advocate of QbD and PAT approaches.
  • Collaborative team leader and expert in cross-functional, matrix environment project leadership requiring risk assessment, priority alignment, and development and coordination of internal and external strategic alliances.